Table 1 Antibiogram of Gram- clinical isolates by BAL samples.
K. pneumoniae (patient #1) | K. oxytoca (patient #2) | P. aeruginosa (patient #3) | E. coli (patient #5) | A. baumannii (patient #5) | P. aeruginosa (patient #6) | |
|---|---|---|---|---|---|---|
Ampicillin | ≥32 (R) | 16 (R) | ≥32 (R) | ≥32 (R) | ≥32 (R) | ≤2 (S) |
Amoxycillin/Clavulanic acid | ≥32 (R) | ≤2 (S) | ≥32 (R) | 16 (R) | ≥32 (R) | 4 (S) |
Piperacillin/Tazobactam | 64 (R) | ≤4 (S) | 8 (S) | 64 (R) | ≥128 (R) | n.d. |
Cefoxitin | ≤4 (S) | ≤4 (S) | n.d. | ≤4 (S) | n.d. | n.d. |
Cefotaxime | ≤1 (S) | ≤1 (S) | ≥64 (R) | ≥64 (R) | ≥64 (R) | ≤1 (S) |
Ceftazidime | ≤1 (S) | ≤1 (S) | 4 (S) | 16 (R) | ≥64 (R) | ≤1 (S) |
Cefepime | ≤1 (S) | ≤1 (S) | 2 (S) | ≥64 (R) | ≥64 (R) | ≤1 (S) |
Ertapenem | ≤0.5 (S) | ≤0.5 (S) | ≥8 (R) | ≤0.5 (S) | ≥8 (R) | ≤0.5 (S) |
Imipenem | ≤0.25 (S) | ≤0.25 (S) | 1 (S) | ≤0.25 (S) | ≥16 (R) | 1 (S) |
Meropenem | ≤0.25 (S) | ≤0.25 (S) | 2 (S) | ≤0.25 (S) | n.d. | ≤0.25 (S) |
Amikacin | ≤2 (S) | ≤2 (S) | ≤2 (S) | 4 (S) | n.d. | 4 (S) |
Gentamicin | ≤1 (S) | ≤1 (S) | ≤1 (S) | ≥16 (R) | ≥16 (R) | ≤1 (S) |
Ciprofloxacin | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | ≥4 (R) | ≥4 (R) | ≤0.25 (S) |
Tigecycline | 1 (S) | ≤0.5 (S) | n.d. | ≤0.5 (S) | 2 (i.e.) | n.d. |
Fosfomycin | ≤16 (S) | ≤16 (S) | n.d. | ≤16 (S) | ≥256 (R) | n.d. |
Nitrofurantoin | n.d. | n.d. | n.d. | ≤16 (S) | n.d. | 128 (R) |
Colistin | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) | 1 (S) |
Trimethoprim/Sulfamethoxazole | ≥320 (R) | ≤20 (S) | n.d. | ≥320 (R) | ≥32 (R) | ≤20 (S) |
